As COVID-19 continues to fade as a primary concern in the U.S., analysts are naturally starting to talk about the pace of recovering economic activity. That includes just about every sector and industry that has been impacted by the pandemic-driven restrictions on social gathering, mask-wearing mandates and more, including the Consumer Discretionary sector, which includes […]
Read MoreEver since coronavirus found its way to American shores, a lot of media attention has been given to the Healthcare sector – and especially to the Biotechnology industry, where many of the biggest names across the world have been working hard to develop effective treatments for the disease. As of this writing, vaccinations have steadily […]
Read MoreFor the last year and a half, the Aerospace industry, which includes commercial airlines has been one of the biggest, unquestioned losers in the stock market. Yes, the biggest portion of that drop comes from the reality that the industry took some of the biggest drawdowns in the market starting in February 2020 as commercial […]
Read MoreThe last year has seen a lot of different storylines emerge. Companies around the world found ways to evolve, but even so there are still significant challenges ahead. COVID is still a thing, even while pandemic-driven restrictions begin to ease, and that means that a complete “return to normal” as we tend to think of […]
Read MoreOver the last year, COVID-19 has forced businesses in just about every segment of the economy to find ways to adjust. The adoption by corporate America to work-from-home models helped keep a lot of people working, and one of the most intriguing success stories that I think will continue to be told for years to […]
Read MoreBuy Price: $250.00 or better Sell Price: TradersPro Sell Signal Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company’s vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and […]
Read More